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Risk assessment is a procedure normally carried out prior to decision-making on the release of 
genetically modified organisms (GMOs) into the environment. Most countries dealing with the release of 
GMOs have appropriate guidelines. The objectives of this paper are to critically examine the risk 
assessment provisions of the Malaysian Biosafety Act (2007), and to compare it with several risk 
assessment provisions in the Cartagena Protocol, as well as regulations in developed countries. There 
are inadequacies in the risk assessment provisions of the Malaysian Biosafety Act (2007 Act), 
compared to those of the Cartagena Protocol, as well as those found in European Commission 
Directives. Although the central objective of the 2007 Act was similar to the Cartagena Protocol, the Act 
was found to be very basic with only a brief provision on risk assessment and there is no specific 
coverage on the socio-economic and ethical aspects as well as the precautionary approach. It is hoped 
that these inadequacies will be improved upon, in order to bring the Malaysian Biosafety Act closer to 
the level seen in the biosafety laws of more developed countries and to ensure adequate level of 
protection for the Malaysian people against any adverse effects of GMOs and products. 
 






Nowadays, with the emergence of new genetically 
modified organisms (GMOs) into the market, biosafety 
has become one of the major challenges faced by 
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such organisms. There is a need to assess their potential 
adverse effects on human, as well on the environment. 
With more and more GMOs entering the world markets or 
are in the process of authorization (Zel et al., 2008), 
tracing and identifying them are becoming increasingly 
complicated tasks. Modern biotechnology has broadened 
the scope of genetic changes made to foods and food 
products, and widened their possible sources. Genetically 
modified (GM) foods are not necessarily less safe than 
those produced through conventional means. Hence, the 
assessment of GM foods and food products does not 
require a substantial change in established principles 







(Miller, 1999). According to Madsen and Sandoe (2007), 
from the early stages of genetic engineering, legal 
frameworks were set up to ensure the safe development 
of this technology. 
Risk assessment is one of the major steps that have to 
be highlighted when dealing with GMOs, especially since 
they may become deregulated (as in the U.S.), may 
become authorised for limited use, such as importation 
for use as food (as in the EU), or specific products 
derived from specific GMOs may become authorised (as 
in PR China) (Jensen, 2009). The concept of risk 
operates as a substantial filter: If it proves riskless 
enough in a due procedure, an artefact may enter the 
common market and enjoy active legal protection by the 
regulator. In this way, the regulator aims at protecting the 
environment and its citizens from biological pollution 
whilst at the same time creating a market for GM foods 
and products (Valve and Kauppila, 2008). 
According to Raybould et al. (2010), a risk assessment 
cannot prove that an activity is safe. However, acceptable 
risk can be demonstrated by sufficient corroboration of 
risk hypotheses that postulate the absence of harm 
resulting from that activity. Risk assessment can be 
defined as a tool to identify and evaluate the potential 
adverse effects of living modified organisms on the 
conservation and sustainable use of biological diversity in 
the potential receiving environment, taking also into 
account risks to human health. It can also be used by 
competent authorities to make informed decisions 
regarding living modified organisms (Cartagena Protocol 
on Biosafety, 2000). 
Concerns that unintended and unexpected side effects 
might arise from GMOs, as a result of the genetic modifi-
cation processes used, thereby adversely impacting 
human and animal health, have attracted attention from 
both the scientific community and the general public. 
However, the potential occurrence of side effects from 
non-GMOs must also be highlighted (Kok and Kuiper, 
2003). Scientists have provided better tools for the 
assessment and evaluation of novel plant products, now 
or in the future. These include molecular characterisation, 
toxicological assessment, nutritional assessment and 
allergenicity. Molecular characterisation is more focused 
on the identification of the exact genetic construct that 
was inserted into the host plant genome and to assess 
the possibility of insertional mutagenic effects. In toxicolo-
gical assessment, the main focus is on well-characterised 
single compounds and, until recently, not so much on 
complex products (Pryme and Lemboke, 2003). Taking 
into account these practical aspects, as well as ethical 
issues that are related to the performance of animal 
toxicity studies, it is clear that this type of study should 
only be performed if there are clear-cut questions that 
form the basis of the study (Kok et al., 2008). 




For the time being, GMOs should be assessed within 
the framework of risk analysis. In addition, the science-
based technologies, with well functioning regulatory 
systems can inject the desired confidence and aware-
ness into the public through risk assessments (Niang, 
2004). The main idea of this framework is to decide 
whether to accept the release of GMOs or not, or about 
whether or not to allow the GMOs to enter the human 
food chain and should be based on scientific risk 
assessment processes. It is internationally accepted that 
risk assessment of GMOs should focus on two particular 
areas; human health and environmental hazard. Here, 
two concepts have to be incorporated into the regulatory 
frameworks governing GMOs: That of substantial 
equivalence, which is used to assess risks posed to 
human health (OECD, 1993a), and that of familiarity, 
which is used in environmental risk assessment (OECD, 
1993b).  
Although, the concept of substantial equivalence in the 
safety assessment of GM foods is new, the primary 
concept of comparing newly developed products or tech-
niques to existing ones has long been applied in various 
fields, including agriculture, and science, and technology 
(Shauzu, 2000). That notwithstanding, the substantial 
equivalence concept is seen as a comparative advance-
ment in spotlighting the similarities and differences 
between GM foods and their conventional equivalents. 
Concurrently, it conveys the view that the perception of 
substantial equivalence is neither a safety assessment in 
itself nor an endpoint. Instead, it is just the starting point 
of the safety assessment. Miller (1999), also stated that 
substantial equivalence is a conceptual tool for food 
producers and government regulators and not a scientific 
formulation, since there is no specification and limits to 
the kind or amount of testing needed for new foods. For 
the first time, the idea of substantial equivalence was 
practically applied on GMOs in the safety assessment of 
the Flavr Savr tomato prior to placing them on the U.S. 
market in 1994. The collected data from field trials and 
from the analyses of the molecular and chemical 
composition showed that the GM tomato corresponded to 
the non-modified parent plant, with the exception of the 
novel commenced traits, which then became the subject 
matter of further studies with a view to establishing food 
safety (Schauzu, 2000). 
Despite this focus on risk assessment and prevention, 
GM crops have given rise to controversies over the last 
10 to 15 years. It is argued that one reason for this is that 
the early regulatory frameworks did not adequately 
address the concerns that seem to underlie public resis-
tance to GM crops. Some of these concerns are about 
risks which lie beyond the issues addressed by the 
authorities that approve GM crops. The objectives of this 
paper is to critically examine the  risk  assessment  provi- 
 
 




sions of the Malaysian Biosafety Act (2007), and to 
compare it with several risk assessment provisions in the 
Cartagena Protocol (2000), as well as regulations in 
developed countries.  
 
 
RISK ASSESMENT IN THE MALAYSIAN BIOSAFETY 
ACT 
 
The Malaysian Biosafety Act (2007) was drafted to be in 
line with the National Biodiversity Policy (1998) and the 
National Biotechnology Policy (2005), and it covers only 
modern biotechnology activities. Malaysia signed the 
Cartagena Protocol on Biosafety in the year 2000 and 
ratified it on September 3, 2003. The protocol took effect 
on December 2, 2003. Following her ratification of the 
Cartagena Protocol, Malaysia passed the Biosafety Act 
on July 11, 2007. The 2007 Act states that before GMOs 
or related products can be imported, prepared, and 
placed on the market, they shall go through a scientific 
risk assessment before approval by the National 
Biosafety Board (NBB). 
The Act, which also established the NBB is meant to 
regulate the release, importation, exportation and con-
tained use of living modified organisms (LMOs), and the 
release of products of such organisms. Its objective is to 
protect human, plant and animal health, the environ-
mental and biological diversity. The Act makes it clear 
that, where there are threats of irreversible damage, lack 
of full scientific evidence may not be used as a reason 
not to take action to prevent such damage, and to provide 
for matters connected therewith. 
The Act consists of seven main parts. Part 1 deals with 
preliminary issues. Part 2 relates to the establishment of 
the NBB, whilst Part 3 deals with approval for release and 
import. Part 4 dwells on notification for export, contained 
used and import for contained use, and Part 5 concerns 
risk assessment and management. Part 6 relates to 
enforcement, whilst the final part, Part 7, is on miscella-
neous matters. This paper will discuss Part 5 of the Act, 
that is, risk assessment and risk management in relation 
to the Cartagena Protocol, as well as regulations in other 
developed countries. 
Since the Biosafety Act (2007) contains only the core 
provisions, details of the risk assessment and manage-
ment procedures are to be developed by the Department 
of Biosafety, Ministry of Natural Resources and 
Environment (NRE). The Act provides for the assessment 
of the risks and adverse effects that LMOs will have, or 
are likely to have on human, plant and animal health, the 
environment and biological diversity. It also provides for 
the proposed measures that should be undertaken to 
prevent, reduce or control the risks and adverse effects 
that such LMOs and products of such organisms will 





health, on the environmental and biological diversity. Part 
5 of the Act also talks about emergency response plans, 
which provide safety measures and procedures 
necessary for the protection of human and animal health, 
the environment and biological diversity against harm or 
damage caused directly or indirectly by LMO or products 
of such organisms, as well as all necessary measures to 
be taken in the event of an emergency. 
Due to concerns of possible risks with GMOs, the 
establishment of the biosafety act in Malaysia is 
important in advancing the development of modern 
biotechnology. The Act also contains provisions on the 
mechanisms and procedures (risk assessment and risk 
management) by which information about GMOs or their 
presence in  foods or products must be disclosed to 
importing countries and consumers (such as, labelling 
and identification). Furthermore, public concern and the 
unknown risks of the GMOs to humans and environment 
compel the need for disclosure. It is expected that this 
Act will eventually cover virtually all forms of biotech-
nology research and development, and perhaps most 
food imports, produced and processed in the country. 
Moreover, the Act should be used to ensure that GMOs 
and related products are safe for use by humans and 
animals, and harmless to the environment (Mirandah, 
2009).    
 
 
CARTAGENA PROTOCOL ON BIOSAFETY 
 
It has long been recognized that any successful sustaina-
ble development strategy has to strike a balance between 
the interests of trade and concern for the environment. 
The adoption of the Cartagena Protocol on biosafety 
represents a significant achievement in trying to reconcile 
these various concerns, and in assessing the safety of 
GMOs for release into environment. The Protocol is signi-
ficant in regulating products of modern biotechnology. But 
its effectiveness with regard to the protection of 
biodiversity and human health depends on its ability to 
adapt to, and catch up with rapid changes in biotech-
nological research and commercialization. 
The key objective of this Protocol is to ensure an 
adequate level of protection in the areas of safe transfer, 
handling and use of LMOs that may have adverse effects 
on the conservation and sustainable use of biological 
diversity, taking also into account risks to human health, 
and specifically focusing on transboundary movements 
(Cartagena Protocol on Biosafety, 2000). 
Based on the provisions of the Cartagena Protocol on 
biosafety (2000), the following general principles can be 
deduced: 
 
The assessment of risks should be done in ways that 







tion should be paid to the advice of relevant experts and 
international organizations. 
Uncertainties or disagreements should not be taken to 
mean the absence of risk in any particular GMO, or that 
the degree of risk associated with it is tolerable. 
The risks associated with GMOs or products derived 
from them, which have detectable new combinations of 
replicable genetic materials that have been obtained 
through the means of modern biotechnology, should be 
considered in the next generation of the risks posed by 
the non-modified recipients or parental organisms in the 
likely potential receiving environment. 
Risk assessment, as well as the nature and scope of 
information required should be based on the particular 
circumstances of each case, including the particular type 
of GMO involved, the use for which it is intended, and the 
environment where it is to be received. 
 
The protocol also includes some methodologies ob-
tained from pre-existing guidelines in some countries. 
The methodologies generally explain that the process of 
risk assessment may, on the one hand, give rise to a 
need for further information about specific subjects, which 
may be identified and requested during the assessment 
process, whilst, on the other hand, information on other 
subjects may not be relevant in some instances. The 
following are the appropriate risk assessment steps 
provided in the protocol: 
 
An identification of any novel genotypic and phenotypic 
characteristics associated with the LMO that may have 
adverse effects on biological diversity in the likely 
potential receiving environment, taking also into account 
risks to human health; 
An evaluation of the likelihood of those adverse effects 
being realized, taking into account the level and kind of 
exposure of the likely potential receiving environment to 
the LMO. 
An evaluation of the consequences should those 
adverse effects be realized. 
An estimation of the overall risk posed by the LMO, 
based on the evaluation of the likelihood and cones-
quences of the identified adverse effects being realized. 
A recommendation as to whether or not the risks are 
acceptable or manageable, including, where necessary, 
identification of strategies to manage those risks.  
Where there is uncertainty regarding the level of risk, it 
may be addressed by requesting further information on 
the specific issues of concern or by implementing appro-
priate risk management strategies and/or monitoring the 
LMO in the receiving environment.  
 
 
CODEX ALIMENTARIUS COMMISSION 
 
Global guidelines for risk analysis and risk assessment of 




GMOs have been developed by the Codex Alimentarius 
Commission (CAC) in several documents. One of those 
documents, “The Principles Document”, advocates that a 
new GM food product should be assessed for its safety 
by comparing it with food that has an established history 
of safe consumption, in order to identify potential hazards 
requiring further considerations. As noted earlier on, this 
view is typically referred to as the “concept of substantial 
equivalence”. This document also stresses that risk 
managers should take into account uncertainties 
identified in the risk assessment and implement appro-
priate measures to manage them (Codex, 2003). 
 
 
EUROPEAN UNION REGULATIONS ON BIOSAFETY 
 
Presently, within the European Union (EU), seven legal 
instruments, comprising both directives and regulation, 
govern the use of GMOs in areas pertaining to food and 
feed (Table 1). The three central legal frameworks 
directly related to food and feed are Council Directive 
2001/18/EC on the deliberate release into the environ-
ment of GMOs, Regulation (EC) No. 1829/2003 on GM 
food and feed, and Regulation (EC) No. 1830/2003 
pertaining to the traceability and labelling of GMOs and 
the traceability of food and feed products, produced from 
GMOs (EC, 2001, 2003a, b). The first two of these legal 
instruments stipulate a pre-market assessment of GMOs 
and aims at securing market by releasing only those 
GMOs that are safe for humans, animals and the 
environment (Alderborn et al., 2010). The following table 
shows the key EU Directives and Regulations of 
relevance to the growth and marketing of GMOs. 
According to EU legislation, the key elements in 
granting authorization to place a GMO intended for food 
and feed use on the common market include a safety 
assessment carried out by the European Food Safety 
Authority (EFSA), and the availability of validated event 
specific detection methods (European Commission, 
2003a; European Commission, 2002). Mehmet (2011) 
notes that: Article 12 of the New GMO Regulations allows 
the Biosafety Council to conduct a simplified authoriza-
tion procedure by taking into consideration a ‘socio-
economic assessment’, provided that the application is 
accompanied by previously conducted environmental risk 
assessments, and is supported by information indicating 
that there exists no possibility of any harm deriving from 
the GMOs and products derived from them, to human, 
animal and plant health, nor to the environment or 
biodiversity. 
By contrast, under the relevant EU legislation, in res-
pect of genetically modified food and feed for placing on 
the market, Regulation 1829/2003 prescribes a standard 
authorization procedure, a simplified procedure is appli-
cable where the deliberate release  into  the  environment
 
 




Table 1. Key EU directives and regulations of relevance to the growth and marketing of GMOs. 
 
Legal framework Coverage 
Directive 98/81/EC  On the contained use of GMOs. Applies to research stages of product development 
Directive 2001/18/EC 
On the deliberate release into the environment of GMOs and repealing Council Directive 
90/220/EEC 
Regulation (EC) No. 1829/2003 On GM food and feed. Specifies authorization procedure and labelling requirements 
Regulation (EC) No. 1830/2003 
Concerns the traceability and labelling of GMOs and of derived food and feed products. 
Specifies amendments of Directive 2001/18/EC 
Regulation (EC) No. 1946/2003 On transboundary movements of GMOs. Implements the Cartagena Protocol on Biosafety 
Regulation (EC) No. 641/2003 
On detailed rules for GMO authorization with respect to documentation on detection and 
identification methodology 
Regulation (EC) No. 65/2003 On the development and assignment of unique identifiers for GMOs 
 




of genetically modified plants is concerned (Article 7(6), 
Directive 2001/18).  
In the authorization of GMO releases, this may be far 
from being a straightforward process. GMOs are excep-
tionally politicized objects of environmental regulation. 
Moreover, as components of hybrid networks of primary 
production, GMOs have no predetermined boundaries. 
Proceduralization aims to promote legal flexibility and 
reflexivity by increasing the scope of case specific 
discretion. Such space is essential for meaningful public 
participation and for the integration of general policy 
goals and particular environments. In practice, procedu-
ralization shifts the regulatory focus from substantive 
ends to knowledge generation and decision-making 





In this paper, comparison has been made between the 
Malaysian Biosafety Act (2007 Act) and the Cartagena 
Protocol and the EC Directives. Compared to the 
Cartagena Protocol on Biosafety, the central objective of 
the 2007 Act is broadly the same, which is ensuring 
adequate level of protection: Safe transfer, handling and 
use of living modified organisms (LMOs) that may have 
adverse effects on the conservation and sustainable use 
of biological diversity, taking also into account risks to 
human health, and specifically focusing on transboundary 
movements (Cartagena Protocol on Biosafety, 2000). 
Risk assessment in the 2007 Act is very basic com-
pared to that of the Cartagena Protocol and the European 
Commission. Although risk assessment is one of the 
main foci of the Act, the relevant provisions are very brief, 
and there is no specific indication of the actual 
procedures that should be taken. Since the advances in 
gene technology have led to speculation and fears in the 
public regarding its potential risks, the regulatory 
guidelines related to the release of recombinant 
Deoxyribonucleic acid (DNA) in the environment have 
been riddled with inconsistencies (Haguenauer, 1996).  
Such processes have been harmonized in Europe 
through the implementation of the European Commission 
(EC) biotechnology directives. These regulations are 
applied to preclinical research that mainly relates to the 
use of GMOs. Wynne (2005) notes that risk assessments 
are, as a rule, presented as open scientific knowledge, 
but in practice, always framed in a way that supports 
social control and authority. 
Although, scientific knowledge produces, and is used in 
a context of political decision-making, embodies tradi-
tional scientific characteristics, it also holds additional 
properties linked to its influence on social, political and 
economic relations. Therefore, the significance of 
uncertainty cannot be assessed based on quality criteria 
that refer to the scientific content only. Uncertainty must 
also include quality criteria specific to the properties and 
roles of this scientific knowledge within political, social, 
and economic contexts and processes (Maxim and van 
der Sluijs, 2011). Failure to consider scientific uncertainty 
at the interface between science and policy has led to 
numerous controversies with consequences (Keepin and 
Wynne, 1984; Van der Sluijs, 2002). 
As mentioned earlier, the Malaysian Biosafety Act 
consists of 7 main parts. Amongst those, risk assessment 
has become the significant part, which also has an 
equivalent in the Cartagena Protocol. However, the major 
difference between those two procedures is that the 
Cartagena Protocol is more concise and exhaustive in 
explaining and describing the risk assessment procedure 
compared to the Malaysian Biosafety Act. Apart from risk 
assessment and risk management, the 2007 Act does not 
cover socio-economic, and ethical issues, as well as 







approval for release and import, as well as notification for 
export and import for contained use. 
Against this background, it may be suggested that 
socio-economic and ethical requirements, as well as 
precautionary principles should be highlighted and 
properly addressed, since all these aspects have 
considerable impact in shaping public, and, in particular, 
consumer perception and acceptance of GMOs. The 
inadequacies and ambiguities of the Act on these matters 
lead to practical problems in its implementation. How-
ever, compared to the Act, the Cartagena Protocol, whilst 
addressing socio-economic issues, is patchy in precau-
tionary principles and ethical issues, thus making it 
difficult to adopt the guidelines and references without 
having any difficulty to recognize it as one major protocol.  
The Protocol states the importance of socio-economic 
issues in consistence with the impact of LMOs on the 
conservation and sustainable use of biological diversity 
especially with regard to the value of biological diversity 
to indigenous and local communities. From the legal 
provisions of the 2007 Act, it can be observed that all the 
prescriptions will be made by the NRE, based on the 
necessity and needs perceived by the Act with regard to 
GMOs in Malaysia. 
Since the 2007 Act and regulations follow the 
Australian regulations, particularly, the Gene Technology 
Regulation (2001), it demonstrates some similarities with 
the regulations of the developed countries, such as those 
of the EU and the UK. Even though risk assessment and 
risk management are not detailed out in the Act, the 
procedures for actions to be taken in the release of 
GMOs can be seen in the forms supplied by the 
Department of Biosafety, NRE, which is the government 
body that is responsible for management of the biosafety 
aspects of GMOs and GMO-related products, as well as 
all matters generally connected with the modern 
biotechnology process. 
However, there are two situations that should be 
concerned when dealing with risk assessment of GMOs. 
According to Sparrow (2010), the regulation of GMOs can 
be divided into two parts: 1) contained use and 2) 
deliberate environmental release (non-contained use). 
The questions asked in all GM risk assessments will be 
similar for both contained and non-contained use; 
however, the depth of supporting information and detail 
will be far greater for the latter”. It should be clarified here 
that contained use is the production of GMO in the 
laboratory, and typically, that covers work in laboratories, 
greenhouses, and closed industrial production facilities. 
On the other hand, deliberate environmental release 
relates to experimental release and placing on the 
market. 
The 2007 Act dwells upon the two main situations men-
tioned above, but it is not  as  detailed  as  the  equivalent  




provisions in the EC Directives, except for those aspects 
concerning release activities of LMOs for research and 
development purposes in all field experiments, or impor-
tation of LMOs. As mentioned already, these procedures 
are implicitly contained in the risk assessment forms 
supplied by the Department of Biosafety, NRE. The Act 
also highlights export and import for contained use, but 
for general information purposes only. The Act is more 
focussed on the notification of the relevant requirements, 
compliance with the requirements of the importing 
country, specific measures to be taken with regard to 
contained use and the role of the NBB and the NRE in 
handling these situations. 
Similar observations can be made about the Cartagena 
Protocol. Whereas the Protocol does mention the subject 
of risk assessment, its provisions on contained use are 
very limited compared to the EC directives. The Protocol 
is more focussed on the procedures for LMOs intended 
for direct use as food or feed, or for processing. This is a 
sharp contrast from the Act in which contained use is the 





The risk assessment procedures that have been 
implemented worldwide are important. They are needed 
in order to overcome the problems emanating from 
GMOs or related products. In addition, they can improve 
the safety level of GM products intended for public use. 
Hence, they also can help to clarify the objective that 
underlies the production of GMOs. Apart from the risk 
assessment procedures, there are several other methods 
of testing meant to identify and improve the quality as 
well as the safety of GMOs. These tests or methods, 
which have been developed by renowned scientists, 
include the nutritional assessment test, the allergenicity 
test, the toxicity test and the compositional studies. 
These are the well-known tests that GMOs have to go 
through in order to ensure that the safety of the products 
is acceptable to all consumers and members of the 
general public. These procedures if followed appro-
priately will be able to raise the confidence of all parties 
concerned. 
There are inadequacies in the risk assessment 
provisions of the Malaysian Biosafety Act, compared to 
those of the Cartagena Protocol, as well as those found 
in the regulations of more developed countries. It is 
hoped that in the future, those inadequacies will be 
improved upon, in order to bring the Malaysian Biosafety 
Act closer to the level seen in the biosafety regulation of 
more developed countries, such the EC directive. More 
rigorous and clear coverage of the socio-economic, 
ethical and religious aspects regarding GMOs  should  be  
 
 




taken into account to harmonise the Malaysian Biosafety 
Act. Although, the genetic modification has the potential 
to benefit Malaysia and its people, it should be adopted 
under conditions that avoid any potential risks to human 
and to the environment, in accordance to the norms and 
religious acceptance of the people. Adequate regulations 
are necessary to avoid possible environmental and safety 
problems, while caution (precautionary principle) is 
necessary in the face of scientific uncertainties related to 
GMOs which can jeopardize the expected benefits of this 
new science. 
It would also be helpful to carry out more studies in 
other important fields in order to develop more useful 
techniques aimed at improving the reliability of GM food 
safety assessment. Furthermore, the development of new 
techniques could be useful to the improvement and 
assessment of GM crops. More systematic measures and 
research work are required in order to ensure that GM 
foods do not cause or aggravate health problems. There 
should be effective agencies with appropriate authority 
that are charged with the approval of GM foods and 
products. The decisions of such agencies should be 
based on the recommendations of specialized commi-
ttees, organized by or working in conjunction with the 
agencies. In addition, proper consideration should be 
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